icon-folder.gif   Conference Reports for NaTaP  
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria  april 22-26
Back grey_arrow_rt.gif
Improvement in Liver Function and Non-Invasive Estimates of Liver Fibrosis 48 Weeks after Treatment With Ombitasvir/Paritaprevir/r, Dasabuvir, and Ribavirin in HCV Genotype 1 Patients With Cirrhosis
  Reported by Jules Levin
EASL 2015 april 22-26 Vienna austria
Heiner Wedemeyer1, Thomas Berg2, Steven L Flamm3, Graham R Foster4, antonio Craxi5, Dominique Larrey6, Timothy R Morgan7, Michael W Fried8, Fred Poordad9, Roger Trinh10, Sandra Lovell10, Yuanyuan Tang10, Marcos Pedrosa10, Juan-Carlos Lopez-Talavera10, Ira M Jacobson11
1Medizinische Hochschule Hannover, Hannover, Germany; 2Universitatsklinikum Leipzig, Leipzig, Germany; 3Northwestern Feinberg School of Medicine, Chicago, Illinois, United States; 4Queen Marys University of London, Barts Health, London, United Kingdom; 5a.O.U Policlinico "P. Giaccone" Dip. Di
Gastroenterologia ed Epatologia D.B.M.I.S., Palermo, Italy; 6CHU de Montpellier, Hopital Saint Eloi, IRB-INSERM1040,
Montpellier, France; 7Va Long Beach Healthcare System, Long Beach, California, United States; 8University of North Carolina, Chapel Hill, North Carolina, United States; 9Texas Liver Insti tute/University of Texas Health Science Center, San antonio, Texas, United States; 10abbVie Inc., North Chicago, Illinois, United States; 11Weill Cornell Medical College, New York, New York, United States